N′1,N′3-Dimethyl-N′1,N′3-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS)

Cisplatin is an important chemotherapeutic agent in lung cancer treatment. The mechanism of drug resistance to cisplatin is complex and historically has been difficult to overcome. We report here that cisplatin resistant lung cancer cell lines possess high basal levels of reactive oxygen species (ROS) when compared to normal cells and their parental cell counterparts. These resistant cells also have low thioredoxin (TRX) levels which may be one of the contributory factors to high ROS. N′1,N′3-dimethyl-N′1,N′3-bis(phenylcarbonothioyl) propanedihydrazide (elesclomol), an agent known to increase ROS is selectively toxic to cisplatin-resistant cells, while sparing normal cells and the parental counterpart. The cytotoxic effect of elesclomol in resistant cells is accompanied by further decreases in TRX and glutathione (GSH) antioxidant systems, while opposite results were found in parental cells. The ID50 of elesclomol in cisplatin-resistant cells ranged from 5–10 nM, which is well within clinically achievable ranges. N-Acetylcysteine (NAC), which is known to neutralize ROS, can abolish the cytotoxic effect of elesclomol, suggesting that the cytotoxic effect results from increased ROS. Overall, our data suggest that elesclomol selectively kills cisplatin-resistant tumor cells through increased ROS. This agent may hold potential to overcome cisplatin resistance and should be further explored to treat patients who have failed cisplatin therapy.

• Publication year

  2009

• Venue

  Cancers

• Publication date

  2009-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3390/cancers1010023PMID 20535236PMCID 2882109
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Elesclomol induces cancer cell apoptosis through oxidative stress

  2008influential reference
• The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents.

  2008cited by this paper
• Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins.

  2008cited by this paper
• Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-d-glucose under hypoxia in lung cancer cell lines

  2008cited by this paper
• Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.

  2008cited by this paper
• Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate.

  2006cited by this paper
• Overcoming cisplatin resistance by mTOR inhibitor in lung cancer

  2005cited by this paper
• Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.

  2005cited by this paper
• Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine.

  2003cited by this paper
• Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex.

  2001cited by this paper
• Thioredoxin reductase.

  2000cited by this paper
• Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II).

  1999cited by this paper
• Mammalian thioredoxin is a direct inhibitor of apoptosis signal‐regulating kinase (ASK) 1

  1998cited by this paper
• Overexpression of thioredoxin does not confer resistance to cisplatin in transfected human ovarian and colon cancer cell lines

  1997cited by this paper
• Detection of 11q13 amplification as the origin of a homogeneously staining region in small cell lung cancer by chromosome microdissection

  1996cited by this paper

• Copper and cuproptosis: From homeostasis to pathogenesis.

  2026cites this paper
• Nanomedicine leverages cuproptosis-mediated cGAS-STING activation to enhance antitumor immunity.

  2026cites this paper
• Copper-induced cell death mechanisms and their role in the tumor microenvironment

  2025cites this paper
• Cuproptosis: a novel therapeutic mechanism in lung cancer

  2025cites this paper
• Dual-Targeting Ratiometric Fluorescent Probe for Visualizing Changes in HClO and Polarity in Lipid Droplets and Mitochondria.

  2025cites this paper
• Unveiling the Cuproptosis in Colitis and Colitis-Related Carcinogenesis: A Multifaceted Player and Immune Moderator

  2025cites this paper
• Targeting Metabolic Vulnerabilities to Combat Drug Resistance in Cancer Therapy

  2025cites this paper
• Strategies to combat cancer drug resistance: focus on copper metabolism and cuproptosis

  2025cites this paper
• TRIM21 promotes K63-linked ubiquitination of ALKBH5 and suppresses cuproptosis via down-regulation of LIAS in esophageal squamous cell carcinoma

  2025cites this paper
• Ferroptosis and cuproptosis: Metal-dependent cell death pathways activated in response to classical chemotherapy - Significance for cancer treatment?

  2024cites this paper
• Cuproptosis: a promising new target for breast cancer therapy

  2024cites this paper
• The In Vitro Cytotoxic Effect of Elesclomol on Breast Adenocarcinoma Cells Is Enhanced by Concurrent Treatment with Glycolytic Inhibitors

  2024cites this paper
• Copper and Colorectal Cancer

  2024cites this paper
• Mammalian copper homeostasis: physiological roles and molecular mechanisms

  2024cites this paper
• Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives

  2024cites this paper
• Targeting cuproptosis for cancer therapy: Focus on the anti-tumor immune system

  2024cites this paper
• Cuproptosis in cancer: biological implications and therapeutic opportunities

  2024cites this paper
• Cuproptosis in lung cancer: therapeutic options and prognostic models

  2024cites this paper
• Cell death mediated by nanotechnology via the cuproptosis pathway: A novel horizon for cancer therapy

  2023cites this paper
• Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance.

  2023cites this paper
• Elesclomol, a copper-transporting therapeutic agent targeting mitochondria: from discovery to its novel applications

  2023cites this paper
• Cuproptosis-related lncRNAs as potential biomarkers of AML prognosis and the role of lncRNA HAGLR/miR-326/CDKN2A regulatory axis in AML.

  2023cites this paper
• Novel insights into anticancer mechanisms of elesclomol: More than a prooxidant drug

  2023cites this paper
• Polysiloxane-Based Molecular Logic Gate for Dual-Channel Visualizing Mitochondrial pH and Sulphite Changes during Cuproptosis.

  2023cites this paper
• Cuproptosis in lung cancer: mechanisms and therapeutic potential

  2023cites this paper
• NLG-919 combined with cisplatin to enhance inhibitory effect on cell migration and invasion via IDO1-Kyn-AhR pathway in human nasopharyngeal carcinoma cell.

  2023cites this paper
• The mechanism of copper transporters in ovarian cancer cells and the prospect of cuproptosis.

  2023cites this paper
• Copper metabolism and hepatocellular carcinoma: current insights

  2023cites this paper
• Copper in cancer: from limiting nutrient to therapeutic target

  2023cites this paper
• DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma

  2023cites this paper
• The role of Extracellular Vesicles in glycolytic and lipid metabolic reprogramming of cancer cells: Consequences for drug resistance.

  2023cites this paper
• Identification and validation of a novel cuproptosis-related gene signature in multiple myeloma

  2023cites this paper
• Cuproptosis and its application in different cancers: an overview

  2023cites this paper
• Selective Targeting of Cancer Cells by Copper Ionophores: An Overview

  2022cites this paper
• Yeast as a Model to Find New Drugs and Drug Targets for VPS13-Dependent Neurodegenerative Diseases

  2022cites this paper
• Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy

  2022cites this paper
• Targeting Copper Homeostasis Improves Functioning of vps13Δ Yeast Mutant Cells, a Model of VPS13-Related Diseases

  2021cites this paper
• Elesclomol induces copper‐dependent ferroptosis in colorectal cancer cells via degradation of ATP7A

  2021cites this paper
• Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration

  2021cites this paper
• ROS-Mediated Apoptosis in Cancer

  2021cites this paper
• Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies

  2021cites this paper
• Perspective on the treatment of non-small cell lung cancer in the context of potential SARS-CoV-2 infection during the pandemic.

  2021cites this paper
• Growth Hormone-Releasing Hormone in Lung Physiology and Pulmonary Disease

  2020cites this paper
• Computationally predicting clinical drug combination efficacy with cancer cell line screens and independent drug action

  2020cites this paper
• Genipin enhances the antitumor effect of elesclomol in A549 lung cancer cells by blocking uncoupling protein-2 and stimulating reactive oxygen species production

  2020cites this paper
• Biomedical applications of copper ionophores

  2020cites this paper
• Quantitative Estimation of Oxidative Stress in Cancer Tissue Cells Through Gene Expression Data Analyses

  2020cites this paper
• The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol

  2019cites this paper
• Developing Ligands to Target Transition Metals in Cancer

  2019cites this paper
• A high-throughput drug screen identifies auranofin as a potential sensitizer of cisplatin in small cell lung cancer

  2019cites this paper
• Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer

  2019cites this paper
• Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer

  2019cites this paper
• The Anticancer Agent Elesclomol Has Direct Effects on Mitochondrial Bioenergetic Function in Isolated Mammalian Mitochondria

  2019cites this paper
• Mechanism of Lung Carcinogenesis: Electron Transfer, Reactive Oxygen Species, Oxidative Stress and Antioxidants

  2018cites this paper
• The Influence of Metabolism on Drug Response in Cancer

  2018cites this paper
• Autophagy: In the cROSshairs of cancer.

  2017cites this paper
• Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer

  2017cites this paper
• Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer

  2017cites this paper
• xCT expression modulates cisplatin resistance in Tca8113 tongue carcinoma cells.

  2016cites this paper
• Terpenoids as effective compounds for overcoming multidrug resistance in cancer cells

  2015influential citation
• Increased Expression of Eps15 Homology Domain 1 is Associated with Poor Prognosis in Resected Small Cell Lung Cancer

  2015cites this paper
• High performance liquid chromatography: Tandem mass spectrometric determination of cisplatin levels in different visceral pleura layers of rats.

  2015cites this paper
• Inhibition of Autophagy Potentiated the Antitumor Effect of Nedaplatin in Cisplatin-Resistant Nasopharyngeal Carcinoma Cells

  2015cites this paper
• An inverse relationship between resistance to 2-deoxy-D-glucose and glucose starvation in tumor cells under normoxia

  2013cites this paper
• Title: The Relationship of Thioredoxin-1 and Cisplatin Resistance: Its Impact on ROS and Oxidative Metabolism in Lung Cancer Cells Running Title: The impact of TRX1 on ROS and oxidative metabolism

  2012cites this paper
• Synergistic Effects of Hydroxychloroquine on the Activity of Thiomaltol against Melanoma Cancer Cells

  2012cites this paper
• Role of thioredoxin in lung disease.

  2012cites this paper
• Therapeutic Discovery The Relationship of Thioredoxin-1 and Cisplatin Resistance : Its Impact on ROS and Oxidative Metabolism in Lung Cancer Cells

  2012cites this paper
• The Relationship of Thioredoxin-1 and Cisplatin Resistance: Its Impact on ROS and Oxidative Metabolism in Lung Cancer Cells

  2012cites this paper
• Oxidatively Activated DNA‐Modifying Agents for Selective Cytotoxicity

  2011cites this paper
• Selective targeting of breast cancer cells through ROS-mediated mechanisms potentiates the lethality of paclitaxel by a novel diterpene, gelomulide K.

  2011cites this paper